GlaxoSmithKline Pharmaceuticals Balance Sheet Annual
BSE: - | NSE: - | ISIN: - | Sector: -| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Liabilities Shareholders' Equity | 4,323.87 | 4,108.07 | 3,556.62 | 3,326.58 |
| Cash Equivalents | 1,391.02 | 435.00 | 0.00 | 0.04 |
| Other Liabilities Total | 260.07 | 249.11 | 247.56 | 255.49 |
| Common Stock Total | 169.41 | 169.41 | 169.41 | 169.41 |
| Other Current Assets Total | 54.39 | 26.39 | 23.93 | 23.29 |
| Total Assets | 4,323.87 | 4,108.07 | 3,556.62 | 3,326.58 |
| Current Portof LT Debt/ Capital Leases | 16.00 | 7.46 | 12.20 | 12.08 |
| Total Equity | 2,267.42 | 1,951.31 | 1,777.64 | 1,741.27 |
| Long Term Investments | 14.96 | 0.81 | 0.94 | 1.09 |
| Retained Earnings( Accumulated Deficit) | 2,098.01 | 1,781.90 | 1,608.23 | 1,571.87 |
| Total Common Shares Outstanding | 16.94 | 16.94 | 16.94 | 16.94 |
| Tangible Book Valueper Share Common Eq | 133.46 | 114.40 | 103.54 | 100.77 |
| Total Liabilities | 2,056.45 | 2,156.75 | 1,778.98 | 1,585.31 |
| Total Debt | 33.27 | 9.95 | 18.67 | 15.54 |
| Short Term Investments | 1,430.12 | 1,959.26 | 1,792.65 | 1,619.18 |
| Cashand Short Term Investments | 2,821.14 | 2,498.10 | 1,856.82 | 1,654.12 |
| Total Receivables Net | 273.11 | 384.77 | 371.99 | 341.93 |
| Notes Payable/ Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Receivable- Trade Net | 273.11 | 301.50 | 231.07 | 206.45 |
| Property/ Plant/ Equipment Total- Net | 306.44 | 283.86 | 310.73 | 315.12 |
| Total Current Liabilities | 1,779.10 | 1,905.15 | 1,524.95 | 1,326.37 |
| Total Inventory | 457.55 | 481.74 | 525.05 | 459.97 |
| Accounts Payable | 570.22 | 708.25 | 625.41 | 427.79 |
| Other Currentliabilities Total | 1,192.88 | 1,033.47 | 773.13 | 791.79 |
| Total Long Term Debt | 17.27 | 2.49 | 6.47 | 3.46 |
| Intangibles Net | 6.56 | 13.33 | 23.55 | 34.09 |
| Other Long Term Assets Total | 211.18 | 185.68 | 191.70 | 179.84 |
| Note Receivable- Long Term | 178.53 | 214.50 | 231.27 | 302.18 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 3,606.20 | 3,409.88 | 2,798.42 | 2,494.26 |
| Capital Lease Obligations | 17.27 | 2.49 | 6.47 | 3.46 |
| Accumulated Depreciation Total | - | -295.62 | -283.13 | -255.54 |
| Accrued Expenses | - | 155.98 | 114.21 | 94.71 |
| Long Term Debt | - | 0.00 | - | - |
| Prepaid Expenses | - | 18.89 | 20.62 | 14.96 |
| Cash | - | 103.85 | 64.17 | 34.90 |
| Property/ Plant/ Equipment Total- Gross | - | 565.16 | 579.93 | 550.35 |
GlaxoSmithKline Pharmaceuticals Quick Links
GlaxoSmithKline Pharmaceuticals Dividend GlaxoSmithKline Pharmaceuticals Bonus GlaxoSmithKline Pharmaceuticals News GlaxoSmithKline Pharmaceuticals AGM GlaxoSmithKline Pharmaceuticals Rights GlaxoSmithKline Pharmaceuticals Splits GlaxoSmithKline Pharmaceuticals Board Meetings GlaxoSmithKline Pharmaceuticals Key Metrics GlaxoSmithKline Pharmaceuticals Shareholdings GlaxoSmithKline Pharmaceuticals Profit Loss GlaxoSmithKline Pharmaceuticals Cashflow GlaxoSmithKline Pharmaceuticals Q1 Results GlaxoSmithKline Pharmaceuticals Q2 Results GlaxoSmithKline Pharmaceuticals Q3 Results GlaxoSmithKline Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.